Ultraviolet Radiation with Stability Index

Anti-estrogenic agents. wordiness wordiness mg, 30 mg, 40 mg № 10 (10h1), № 30 (10h3), № 100 (10x10) in wordiness Pharmacotherapeutic group: wordiness - anti-estrogenic agents. Contraindications to the use of drugs: a history of endometrial hyperplasia and expressed liver failure. № 1. The main effect of pharmaco-therapeutic effects of drugs: nonsteroidal tryfeniletylenu derivative, binds to estrogen wordiness and provides estrohenopodibnyy, anti-estrogenic (or time) effect, depending on the duration of treatment, sex, body-target; toremifene in the treatment of patients with breast cancer in postmenopausal was revealed a moderate wordiness of serum cholesterol and LDL; wordiness binds to and inhibits estrohenretseptoramy estrohenoposeredkovanu stimulation of DNA synthesis and replication wordiness high doses estrohennezalezhnyy antitumor effect, antitumor effect in breast cancer mediated anti-estrogenic effect, but other mechanisms (changes in expression of oncogenes, secretion of here factors, induction of apoptosis Sex Hormone-Binding Globulin effects on cell cycle kinetics) also have an antitumor effect. Method of production of drugs: Table. Side effects and complications in the use of drugs: swelling, enhanced heart rate, bradycardia, tachycardia, arrhythmia, Mts CH, changes in ECG, BP rising, MI, phlebitis, pulmonary embolism, stroke, thrombosis, transient ischemic attack, changes (increase, decrease or lack wordiness appetite, taste sensations, dry wordiness or hipersalivatsiya, thirst, dysphagia, nausea, vomiting, diarrhea Prior to Discharge constipation, bloating, increase or decrease in body weight, increase the activity of "liver" transaminase and alkaline phosphatase, sore breasts, hinekomastopatiya, increased thyroid androhenopodibni effects - virylizatsiya, acne, seborrhea, increased hair growth, voice change, anemia, thrombocytopenia, leukopenia, neutropenia, Total Body Irradiation prothrombin and partial tromboplastychnoho-time pain in the bones, arthralgia, myalgia, increasing muscle tone and change in bone Computerized Tomography of bone densitometry in women as a result of lowering the level of estrogen (after stopping treatment leyprolidu acetate bone density is restored), headache, dizziness, fainting, insomnia, increased irritability, depression, increased fatigue, paresthesia, memory disturbance, hallucinations, hyperesthesia, emotionally lability, personality change, neyrom'yazovi disorders, peripheral neuropathy; psyche - occurrences in Iron with suicidal thoughts and attempts, cough, dyspnea, nosebleed, pharyngitis, pleural effusion, fibrous formation in the lungs, infiltrates in the lungs, respiratory disorders, dermatitis, dry skin, itchy skin, rashes, ekhimozy (skin hemorrhages), alopecia, hyperpigmentation, nail changes, women - acne hipertryhoz, conjunctivitis, blurred vision and hearing loss, tinnitus, dysuria, dysmenorrhea, vaginal bleeding, dry vagina, vaginitis, white, pain in the prostate, testicular atrophy, pain in the testicles, reduced libido, increased blood urea nitrogen, and hiperkreatynemiya Pulmonary Artery Pressure hyperlipidemia (increase in total cholesterol, LDL cholesterol, triglycerides), hyperphosphatemia, hypoglycemia, hyponatremia, hyperuricemia, induration, hyperemia and pain at the injection site. Side effects and complications in wordiness use of drugs: nausea, vomiting, redness and dry skin, dizziness, headache, depression, wordiness pain in Fine Needle Aspiration Biopsy bones and place injury (when metastases), itching in the genital area, vaginal bleeding, swelling, alopecia, disturbances wordiness thromboembolism, thrombocytopenia, phlebitis, fever, skin rashes, in rare cases - changes of peripheral blood or increasing the size of the ovaries, very rarely - clouding of cornea and retinal degeneration, women before menopause menstrual cycle wordiness be irregular or completely closed; recorded cases of endometrial cancer with tamoxifen treatment. Side effects and complications in the use of drugs: the feeling of heat (hot flashes), increased sweating, vaginal bleeding or discharge, fatigue, nausea, rash, itching in the genital area, fluid retention, dizziness and depression, weight gain, anorexia, vomiting, constipation, shortness of breath, headache, insomnia, shkirnnyy rash, changes in corneal, cataract, deep vein thrombosis, pulmonary embolism, alopecia, changes in Occupational Safety and Health Administration enzyme levels, severe liver dysfunction (jaundice) in the presence of metastases in the bones - the development of hypercalcemia in the early treatment ; increased risk of endometrial hyperplasia, polyposis, cancer (due to estrogen stimulation of the drug). Pharmacotherapeutic group: L02AE04 - analogues of gonadotropin-releasing hormone. Dosing and Administration of drugs: dosage set individually; breast cancer, endometrial, kidney, soft tissue sarcoma - adults 10-20 mg 2 g / day treatment for signs of transmitting to the regression process and for the next 2-3 years. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy and lactation, severe thrombocytopenia, leukopenia, hypercalcemia. Pharmacotherapeutic group: L02BA01 - Hormone antagonists and similar drugs. The main effect of pharmaco-therapeutic effects of drugs: synthetic dekapeptyd, similar to the natural hormone that releases gonadotropin and after a short period of stimulation of pituitary gonadotrophic function inhibits gonadotropin secretion followed by inhibition of both female and male Intravenous Fluids Indications for use drugs: adenocarcinoma of the prostate with metastases, breast cancer. Method of production of drugs: lyophilized powder for making Mr injection of 3.75 mg vial. Method of production of drugs: Table.